Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy (LuTectomy)
Study of the Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Radionuclide Therapy Prior to Radical Prostatectomy in Men With High-risk Localised Prostate Cancer
Sponsor: E.J. Whitten Foundation Prostate Cancer Research Centre
Listed as NCT04430192, this PHASE1/PHASE2 trial focuses on Prostatic Neoplasms and remains ongoing. Sponsored by E.J. Whitten Foundation Prostate Cancer Research Centre, it has been updated 9 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Dec 2024 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jun 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Jun 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- E.J. Whitten Foundation Prostate Cancer Research Centre
- Endocyte
- Medical Research Future Fund
- Movember Foundation
- Peter MacCallum Cancer Centre, Australia
For direct contact, visit the study record on ClinicalTrials.gov .